



CONTEXTVISION AB THIRD QUARTER 2016

Q3 HIGHLIGHTS

- Good results in deep learning competition
- Sales increased by 19%
- Broadened digital pathology research program

Q3 FINANCIAL DATA

- Sales of 20.3 MSEK (17.0)
- Operating result of 2.0 MSEK (2.9) and operating margin of 9.6% (17.2%)
- Research costs of 4.7 MSEK (2.3)
- Earnings per share of 0.2 (0.3) SEK



VERY STRONG QUARTER WITH HIGH SALES GROWTH AND BREAKTHROUGH WITHIN ARTIFICIAL INTELLIGENCE

ANITA TOLLSTADIUS, THE COMPANY'S CEO COMMENTED:

Q3 was a strong quarter for ContextVision with sales reaching 20,3 million SEK, which is 19 percent higher than Q3 2015. As a result, the operating profit was 2,0 MSEK and the operating margin was 9,6 percent. The research program within artificial intelligence technology had a major breakthrough and Contextvision placed second in a prestigious competition focused on deep learning in digital pathology.

Our sales have increased significantly this quarter, partly as a result of a solid customer base and a versatile ultrasound product portfolio. The products for 2-D ultrasound image enhancement offer great flexibility and can be customized and integrated into a wide range of equipment. This has allowed us to broaden sales to present customers as our software is integrated into further models. The sales generated from our 2-D ultrasound portfolio increased by 21 percent.

Our strategy toward specializing in image analysis and artificial intelligence has shown positive results. During the third quarter we embarked on an official challenge; the Tumor Proliferation Assessment Challenge (TUPAC) 2016 within the MICCAI. Participating teams were given a dataset of whole slide images and one of the tasks was to assess tumor proliferation speed by applying machine learning algorithms. Automated counts offer an objective assessment, but these need to surpass the performance of human observers and be applicable to the full images in order to become truly valuable in routine healthcare. We achieved very good results and placed second in the key task, to automatically generate the proliferation score, and third in the other tasks within the challenge*. Many prestigious teams participated, including both highly reputable academic teams, and research groups from companies like IBM and Microsoft.

Breast cancer

As planned, various feasibility studies are ongoing and we have broadened our Eurostar research program to include breast cancer in addition to prostate cancer. Breast cancer is the most common cancer in women in the world, with almost 1.7 million new cases diagnosed in 2012. This represents about 25 percent of all cancers in women. Treatments have improved over the last decades and screening programs are now established in many countries. However, there is a great need for decision support tools for the pathologists assessing the biopsies used for diagnosis.

The evaluations of the biopsies by pathologists are crucial for the choice of treatment and overall survival. For example, the assessment of tumor growth (tumor proliferation speed) is a central indicator when evaluating the cancer patients' prognosis. Breast cancer patients

with high tumor proliferation speed have worse outcomes compared with patients with low tumor proliferation speed. Thus, the assessment of this biomarker influences the decisions for the treatment plan. Counting the number of dividing cells in hematoxylin & eosin (H&E) stained histological slide preparations is the most common way to assess proliferation speed. Although this task is routinely performed in almost every pathology practice, there is room for improvement to ensure the right treatment for each patient.

Strong sales growth

Our unique products for 3-D ultrasound imaging targets high-end equipment for obstetrics and gynecology, an area that continues to grow. Our sales in this segment grew by 20 percent compared to last year.

During this quarter the MRI (magnetic resonance imaging) segment also contributed to the substantial sales increase. Due to the high costs for this equipment, this market is well consolidated compared to the ultrasound market. We have close relationships with several MRI manufacturers, particularly in Asia, and provide software for a range of MRI systems. When healthcare providers are reluctant to invest heavily into new MRI equipment, the manufacturers see the opportunities to support their business by offering upgrades of the existing products in the field. ContextVision software adds such opportunities by allowing an upgrade of the image quality, resulting in extraordinary high sales within MRI during this quarter.

Sales have continued to shift this year with regard to the proportion of sales generated in our three regions. We grew in all geographic markets in Asia, and as a result we increased by 41 percent in this region compared to the previous year. We have several contracts with high-volume customers in the high- and mid-range ultrasound segment, and these continue to grow in par with increased healthcare needs.

In Europe the increase was 16 percent which is largely related to the generation of new customers earlier this year, and to the fact that the rest of our customers are generating very stable sales. The U.S. sales were lower than last year because of the change in the portfolio made by one of our major customers, but the rest of the market is stable, including veterinary X-ray where we continue to have a very strong position.

We are proud that we continue to show overall positive results whilst investing heavily in new research. When looking at our core business alone, we can see that the underlying operating margin for the quarter has improved; it was 33 percent in Q3 2016, compared to 31 percent in the same quarter last year. The cost for new research activities was 4,7 MSEK in the quarter, which is an increase of more than 100 percent compared to Q3 last year. The change in cash flow was 0,4 MSEK for the period, and our cash position continues to be very strong.

We are very pleased about the new steps we have taken within the digital pathology research program and the preliminary results look very promising. The strong sales numbers are supporting our investments in future growth and allow us to not only broaden our research program, but also identify and evaluate further opportunities.

** Part of the SLDESUTO project, which receives funding from the Eurostars-2 Joint Program with co-funding from the European Union's Horizon 2020 research and innovation program. This is a joint project between ContextVision AB, in Linköping, Sweden and the [eHealth unit of HES-SO, University of Applied Sciences Western Switzerland in Sierre](#), Switzerland. State-of-the-art [machine learning](#) algorithms, including [deep learning](#), will be used to train the software to automatically recognize, identify and classify abnormal patterns in digital images with a variety of pathologies. The purpose of this project is to use unique technology and knowledge to develop a Decision Support Toolbox (DST), that will support the pathologists in their challenging task to diagnose and evaluate the prognosis of different types of cancer.*

THIRD QUARTER 2016

NET SALES AND OPERATING PROFIT

NET SALES

- The sales for the third quarter 2016 for ContextVision was 20.3 MSEK, which represents an increase of 19% compared to the same period last year.
- The currency exchange rates had an average effect on sales of 6% during the quarter, with the JPY exchange rate representing most of the effect, while USD and EUR changes had minor effect.

OPERATING PROFIT AND MARGIN

- The operating result was 2.0 MSEK (2.9) with an operating margin of 9.6% (17.2%).
- The cost for research within new areas (not capitalized) ended at 4.7 MSEK (2.3) during Q3.
- Capitalization is recorded as intangible fixed assets only when product development meets certain requirements. Capitalized costs for development of one product (total 0.3 MSEK) has been recorded during the quarter.
- The higher number of employees in combination with the lower level of capitalization is explanation to the higher personnel costs for the quarter, compared to the same quarter last year.
- The ongoing research activities in the company has also had an effect on the external costs for the period.

CASH-FLOW AND FINANCING

- Cash flow for the quarter represented a positive change of 0.4 MSEK (3.6).
- Cash amounted to 39.0 MSEK (35.7) at period end.
- Equity at period end amounted to 59.0 MSEK (56.0) giving an equity ratio of 78.9% (79.3%).

GOVERNMENT GRANT

- ContextVision was awarded a EU grant in 2015, together with its academic partner University of Applied Sciences an Arts Western Switzerland (HES-SO).
- The company's total part of the grant is TEUR 404, and it will be paid out during a three-year period.
- The first part of the grant (0.6 MSEK) was received in Q4 2015.

- The grant for 2016 is expected to be received in Q4, and will then be recorded as a cost decrease. The grant has therefore not been recorded in the P&L statement and has not affected the results for Q3.

EMPLOYEES AND MANAGEMENT

- At period end the company had 42 (39) employees of which 21 (19) are dedicated to research and development. 2 employees are located in the USA and 1 in China.

CONTEXTVISION GROUP

- The group consists of ContextVision AB (publ), company registration number 556377-8900 as the parent company, and ContextVision Inc Corp registration number 36-4333625 State of Illinois, USA, as the wholly owned subsidiary.
- Operations in the group are conducted primarily in the parent company and consist of research and development, sales, marketing and administrative functions.

RISKS & UNCERTAINTIES

- ContextVision's major risk factors include business risks connected to the general global financial situation, to the level of healthcare investment on different markets, currency exchange risks, the company's ability to recruit and keep qualified employees and the effect of political decisions.
- The company's risk factors are described in the annual report 2015. The risks and uncertainties have not changed significantly since then.
- This quarterly report provides a fair and true overview of the company's and the Group's activities, position and results, and describes the risks and uncertainties of significance faced by ContextVision and by the companies in the Group.

SUBSEQUENT EVENTS

- No significant events have occurred during the period between year-end and date of issuance of this report.

The Board of Directors of ContextVision AB
Stockholm 2016-10-26

This report has not been reviewed by the company's auditors.

PRESENTATION AND REPORTING DATES

This quarterly report will be published on the company's website on the 27th of October, 2016.

There will be a video presentation released on the 28th of October, at 09.00 CET.

Please follow the link:

<http://webtv.nu/contextvisionq32016>

Please visit www.contextvision.com for further information, or use shareholderinfo@contextvision.se to send a question directly to management.

REPORTING DATES

Annual General Meeting	April 20, 2016
Q1 result 2016	April 21, 2016
Q2 result 2016	August 18, 2016
Q3 result 2016	October 27, 2016
Q4 and annual result 2016	February 23, 2017

FOR MORE INFORMATION PLEASE CONTACT:

Anita Tollstadius, CEO
Phone +46 (0)8 750 35 50

CONTEXTVISION FAST FACTS

- ContextVision is a spin-off from the Image Processing Laboratory at Linköping University, Sweden. The corporate identity was established in 1983 with the first OEM agreement in radiology in 1987. ContextVision is traded on the Oslo Stock Exchange since 1997.
- ContextVision has a specialist competence within medical image processing and artificial intelligence technologies.
- A world leader in image enhancement using proprietary technology based on GOP.
- ContextVision has entered into a new progressive phase to become a leader within new technologies, such as deep learning.
- The Company is running a research program to take a leading position on the new, fast growing digital pathology market.

THE COMPANY OFFERS:

- 30 years of successful experience in OEM business
- Unprecedented image enhancement for ultrasound, X-Ray, MRI, CT, mammography and iRV.
- Long standing corporate commitment to R&D that ensures timely and rewarding upgrade paths
- Strong customer relationships to ensure their success
- Expert training in image processing for our customers
- Compatibility across different image formats and major computer platforms
- ContextVision's technology enables the company's customers to provide superior digital imaging solutions for hospitals and clinicians. Such solutions promise more rapid and accurate diagnoses, reduced operator eye fatigue, and ultimately, a greater return-on-investment for medical imaging users.

CONSOLIDATED INCOME STATEMENT (SEK 1000)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Net sales	20 334	17 044	57 055	53 484	72 237
Total revenues	20 334	17 044	57 055	53 484	72 237
Goods for resale	-569	-363	-1 490	-1 319	-1 933
Other external costs	-5 266	-3 275	-14 923	-12 484	-18 392
Personnel costs	-11 213	-9 538	-34 315	-30 719	-40 777
Depreciation assets	-1 325	-1 009	-3 491	-3 199	-4 259
Other income ^{1/}	-	76	-	76	77
Operating results	1 961	2 935	2 836	5 839	6 952
Interest income	1	-	-	-	1
Interest cost	-	-3	-2	-1	-1
Results after financial items	1 962	2 932	2 833	5 838	6 952
Tax	-461	-541	-685	-1 176	-1 615
Net results	1 501	2 391	2 147	4 662	5 338
Earnings per share after tax (SEK)	0,19	0,31	0,28	0,60	0,70

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Effect of currency hedging	-2	-38	-195	498	799
Translation difference	29	48	56	140	146
Total other comprehensive income	27	10	-139	638	945
Net result for the period	1 501	2 391	2 147	4 662	5 338
Total comprehensive income for the period	1 528	2 401	2 008	5 300	6 283

FINANCIAL HIGHLIGHTS

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Earnings per share after tax (SEK) before/after dilution	0,19	0,31	0,28	0,60	0,70
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	9,6	17,2	5,0	10,9	9,6
Solidity (per cent)	78,9	79,3	78,9	79,3	78,7

DEFINITIONS

Operating margin: Operating income excluding non-recurring items as a percentage of net sales.

Profit margin: Result after financial items as a percentage of net sales.

Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity.

Solidity (Equity ratio): Equity as a percentage of total assets.

SALES BY REGION (MSEK)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Asia	11,2	7,9	29,2	22,1	31,8
Europe	6,5	5,6	19,5	18,9	25,4
USA	2,6	3,5	8,3	12,5	15,0
Total	20,3	17,0	57,0	53,5	72,2

SALES BY PRODUCT (MSEK)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
XR	2,7	2,6	7,4	8,2	10,2
US 2D	11,1	9,2	32,1	31,2	41,5
US 3D	2,4	2,0	7,4	6,4	9,8
MR	3,6	3,1	8,7	6,7	9,2
Others (iRV, CT, Mammo)	0,5	0,1	1,4	1,0	1,5
Total	20,3	17,0	57,0	53,5	72,2

CONSOLIDATED BALANCE SHEET (SEK 1000)

	Q3 2016	Q3 2015		2015
Intangible fixed assets	15 725	17 442		17 540
Tangible assets	525	600		537
Other financial assets	323	346		254
Inventories	267	593		396
Current receivables	19 079	16 025		18 141
Cash and bank	38 963	35 664		35 644
Total assets	74 883	70 670		72 512
Equity	59 045	56 053		57 036
Provisions	1 105	759		1 194
Current liabilities	14 733	13 858		14 282
Total equity and liabilities	74 883	70 670		72 512

CHANGE IN EQUITY (SEK 1000)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Opening balance	57 517	53 652	57 036	50 753	50 753
Total comprehensive income for the period	1 528	2 401	2 008	5 300	6 283
Closing balance	59 045	56 053	59 045	56 053	57 036

CONSOLIDATED STATEMENT OF CASH FLOWS (SEK 1000)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Result after financial items	1 962	2 932	2 833	5 838	6 953
Depreciation and write-down of assets	1 325	1 009	3 491	3 199	4 260
Unrealized gain/loss on current investments	-2	-38	-195	498	798
Income tax paid	-1 342	-310	-3 325	-1 695	-1 969
Cash flow from operating activities before change in working capital	1 943	3 593	2 804	7 840	10 042
Change in working capital					
Increase (-)/decrease (+) inventories	319	-400	129	-103	94
Increase (-)/decrease (+) current receivables	34	1 140	2 237	-797	-3 751
Increase (+)/decrease (-) liabilities	-1 586	241	101	1 160	2 771
Cash flow from operating activities	710	4 574	5 269	8 100	9 156
Investing activities					
Investments in intangible assets	-260	-973	-1 719	-4 102	-5 269
Investments in tangible assets	-	-	-161	-108	-109
Other financial assets	-69	-31	-69	639	731
Cash flow from investing activities	-329	-1 004	-1 949	-3 571	-4 647
Financing activities					
Cash flow from financing activities	0	0	0	0	0
Cash flow for the period	381	3 570	3 320	4 529	4 509
Change of liquid assets					
Liquid assets at beginning of period	38 582	32 094	35 644	31 134	31 134
Liquid assets at period end	38 963	35 664	38 963	35 664	35 644

PARENT COMPANY INCOME STATEMENT (SEK 1000)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Net sales	20 334	17 044	57 055	53 484	72 237
Total revenues	20 334	17 044	57 055	53 484	72 237
Goods for resale	-569	-363	-1 490	-1 319	-1 933
Other external costs	-6 107	-3 926	-17 394	-14 335	-20 926
Personnel costs	-10 437	-8 922	-32 004	-28 973	-38 405
Depreciation assets	-1 325	-1 009	-3 491	-3 199	-4 259
Other income	-	77	-	77	77
Operating results	1 896	2 901	2 676	5 734	6 789
Interest income	1	-	-	-	-
Interest cost	-	-3	-4	-1	-
Provision for tax allocation reserve	-	-	-	-	-1 800
Dividends from group company	-	-	-	-	433
Results after financial items	1 897	2 898	2 673	5 733	5 422
Tax	-445	-553	-668	-1 152	-1 113
Net results	1 452	2 365	-2 005	4 581	4 310
Earnings per share after tax (SEK)	0,19	0,31	0,26	0,59	0,60

PARENT COMPANY STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Effect of currency hedging	-2	-38	-195	498	799
Total other comprehensive income	-2	-38	-195	498	799
Net result for the period	1 452	2 365	2 005	4 581	4 310
Total comprehensive income for the period	1 450	2 327	1 810	5 079	5 109

FINANCIAL HIGHLIGHTS

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Earnings per share after tax (SEK) before/after dilution	0,19	0,31	0,26	0,59	0,60
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	9,3	17,0	4,7	10,7	9,4
Solidity (per cent)	71,5	72,8	71,5	72,8	70,1

DEFINITIONS

Operating margin: Operating income excluding non-recurring items as a percentage of net sales.

Profit margin: Result after financial items as a percentage of net sales.

Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity.

Solidity (Equity ratio): Equity as a percentage of total assets.

SALES BY REGION (MSEK)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Asia	11,2	7,9	29,2	22,1	31,8
Europe	6,5	5,6	19,5	18,9	25,4
USA	2,6	3,5	8,3	12,5	15,0
Total	20,3	17,0	57,0	53,5	72,2

SALES BY PRODUCT (MSEK)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
XR	2,7	2,6	7,4	8,2	10,2
US 2D	11,1	9,2	32,1	31,2	41,5
US 3D	2,4	2,0	7,4	6,4	9,8
MR	3,6	3,1	8,7	6,7	9,2
Others (iRV, CT, Mammo)	0,5	0,1	1,4	1,0	1,5
Total	20,3	17,0	57,0	53,5	72,2

PARENT COMPANY BALANCE SHEET (SEK 1000)

	Q3 2016	Q3 2015		2015
Intangible fixed assets	15 725	17 442		17 540
Tangible assets	525	600		537
Other financial assets	540	563		471
Inventories	268	593		396
Current receivables	19 037	16 024		18 111
Cash and bank	38 540	35 497		35 570
Total assets	74 635	70 719		72 625
Equity	53 352	51 513		51 542
Provisions	5 200	3 450		5 250
Current liabilities	16 083	15 756		15 833
Total equity and liabilities	74 635	70 719		72 625

CHANGE IN EQUITY (SEK 1000)

	Q3 2016	Q3 2015	NINE MONTHS 2016	NINE MONTHS 2015	FULL YEAR 2015
Opening balance	51 902	49 186	51 542	46 434	46 434
Total comprehensive income for the period	1 450	2 327	1 810	5 079	5 108
Closing balance	53 352	51 513	53 352	51 513	51 542

BASIS OF PREPARATION

The interim condensed consolidated financial statements for the 3:d quarter ended September 30, 2016 have been prepared in accordance with IAS 34 Interim Financial Reporting and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent Company, RFR 2. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as of December 31, 2015. There has been no changes in the accounting principles or methods for calculation during the period.

GLOSSARY

ARTIFICIAL INTELLIGENCE (AI)

Artificial Intelligence is the intelligence exhibited by machines or software.

DEEP LEARNING

Deep learning is the latest very powerful technology within machine learning; machine learning with deep neural networks

DIGITAL PATHOLOGY

Digital pathology refers to the digital images of histopathology samples. The digitalization is achieved by scanning the prepared samples.

FLUOROSCOPY

An X-ray imaging technique that produces real-time images of a patient's internal structures on a TV monitor. Fluoroscopy allows the study of dynamic processes within the body and can be used for guidance in interventional procedures.

GOP® (GENERAL OPERATOR PROCESSOR)

A term for ContextVision's methodology in detecting structures in an image and relating them to their wider context in order to increase visualization accuracy.

GOPICE® (IMAGE CUBICLE ENHANCMENT)

GOPICE® is the family name for ContextVisions real-time 3D volumetric image enhancement product, for OEM embedded software.

GOPVIEW®

The family name for ContextVision's 2D product lines of OEM-embedded software.

IMAGE ANALYSIS

Processing a digital image in order to describe/classify its contents or to extract quantitative measurements.

IMAGE PROCESSING

A generic term used to describe the computation of digital images, typically to enhance or analyze them.

IMAGE ENHANCEMENT

To improve the visual quality of a digital image by increasing the visibility of relevant structures, as in edge/contrast enhancement and the suppression of noise or artifacts.

MACHINE LEARNING

Machine learning is the study of computer algorithms that improve automatically through experience

MAMMOGRAPHY

An X-ray method used to examine the human breast.

MODALITY

A device that generates internal images of the body, such as X-ray, ultrasound, magnetic resonance imaging, and computed tomography.

MRI (MAGNETIC RESONANCE IMAGING)

A non-invasive procedure, generated by variations in strong magnetic fields, that produces a two-dimensional view of an internal organ or structure, especially the brain and spinal cord.

OEM

The acronym for Original Equipment Manufacturer.

REALICE™

REALICE is a volume enhancement and rendering product package for 3D and 4D fetal volume visualization.

US (ULTRASOUND)

A procedure in which high-energy sound waves are bounced off internal tissues or organs to create echoes. The echo patterns are displayed on the screen of an ultrasound machine, forming a picture of body tissues called a sonogram.

XR (X-RAY)

A diagnostic device in which radiation is used to create images for examination of soft and hard tissue, such as muscle and bone.

ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision has decided to take a lead position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing heavily in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D Ultrasound, MRI, X-Ray and Mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit www.contextvision.com.

EUROPE/HEAD OFFICE ContextVision AB, Corp. Sales and Marketing, Kungsgatan 50, SE-111 35 Stockholm, Sweden, Phone: +46 8 750 35 50, Fax: +46 8 750 54 94

RUSSIA ContextVision, Business Sweden, St. Petersburg, Russia, Phone: +7 812 329 2595, Fax: +7 812 329 2597

NORTH AMERICA ContextVision Inc, USA, Phone: +1 720 326 3228

ASIA ContextVision AB, Asia Sales, Stockholm, Sweden, Phone: +46 8 750 35 50, Fax: +46 8 750 54 94

SOUTH KOREA ContextVision, Business Sweden, Seoul, South Korea, Phone: +82 2 739 1462, Fax: +82 2 739 1463

CHINA ContextVision, Beijing, P.R.China, Phone: +86 10 5815 6256, Fax: +86 10 5815 6255

JAPAN Toyo Corporation, Tokyo, Japan, Phone: +81 3 3245 13 51

E-MAIL info@contextvision.se

WEB www.contextvision.com

Image is everything.